WYWenjuan Yin

Wenjuan Yin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wenjuan Yin has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • C M Wang

    Department of Pathology, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou 310022, China

    1 shared publication
  • CanMing Wang

    Department of Pathology The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital) Hangzhou PR China

    1 shared publication
  • ChaoQi Wu

    Department of Pathology The Cancer Hospital of the University of Chinese Academy of Sciences(Zhejiang Cancer Hospital) Hangzhou PR China

    1 shared publication
  • Chaoqi Wu

    Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310022, China; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310018, China

    1 shared publication
  • Chongyong Xu

    Department of Radiology, The Second Affiliated Hospital of Wenzhou Medical University, Yuying Chilldren’s Hospital, Wenzhou, China

    1 shared publication
  • Chunhong He

    Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, 210032, China

    1 shared publication

Latest Publications

  • Open Access

    Aneuploidy of chromosome 8 promotes the mesenchymal lineage during cell fate transitions

    by Cai Liang, Guanchen Li, Qiuqin Zhang, Xinlei Wang, Yu Liu, Wenjuan Yin, Ting Tao, Jinhu Wang, Haishan Gao, Shutao Qi, et al.

    Aneuploidy is present in about 90% human solid tumors. Certain tumors remain addicted to aneuploidy. Paradoxically, artificially induced aneuploidy in normal cells elicits cellular stresses and decreases cell fitness. How aneuploidy initially emerges during tumorigenesis is thus unclear. Using human embryonic stem cells (ESCs) as a model, we show that aneuploid ESCs form immature teratomas with an enrichment of mesenchymal tissues. Specifically, chromosome 8 (chr8) gain, a prevalent form of aneuploidy in human cancers, promotes the expansion of mesenchymal stem cells (MSCs) in teratomas and MSC proliferation in vitro. We further show that human embryonal rhabdomyosarcomas, tumors of mesenchymal origin, lack dominant driver mutations but frequently harbor chr8 gain. Our study suggests a plausible mechanism for aneuploidy emergence during tumorigenesis, links specific aneuploidy to the mesenchymal lineage, and paves the way for identifying vulnerabilities of aneuploid MSCs, which may have important roles in tumorigenesis.


  • Open Access

    Analysis of discordance between mismatch repair and microsatellite instability testing in endometrial cancer

    by Yun Xi, Chunhong He, Xianhua Fang, Jiani C. Yin, Yihua Wang, Hui Wang, Chaoqi Wu, Jianfei Fang, Qian Lai, Pan Liu, et al.


  • Open Access

    Immunological Role of TP53 Somatic Mutation Classification in Human Cancers

    by Jianfei Fang, Ying Yang, Lina Xie, Wenjuan Yin

    Background. TP53 is a very common tumor suppressor gene and has implicated in various cancers. A systematic immunological analysis of TP53 somatic mutation classification in multiple cancers is still lacking. Methods. To assess the immunological value of TP53 somatic mutation classification in various cancers, we integrated a series of bioinformatics methods to analyze the role of TP53 gene across the public databases, such as UCSC Xena, Cancer Cell Line Encyclopedia (CCLE), Ensembl, and GenotypeTissue Expression (GTEx). Results. The results revealed that the TP53 expression level had significant difference in tumor tissues and normal tissues, and it had a high expression level in most malignant tumors. Moreover, the missense mutation is the most common type of TP53 mutation in most cancers. In addition, the Cox proportional hazards model analysis and KaplanMeier (KM) survival analysis demonstrated that the TP53 expression is a high-risk factor in brain lower-grade glioma (LGG), prostate adenocarcinoma (PRAD), and uterine carcinosarcoma (UCS), which is opposite in uterine corpus endometrial carcinoma (UCEC). Besides, compared to the TP53 nontruncating mutation classification samples, we found that TP53 truncating mutation samples had lower TP53 expression levels in certain types of cancer. Notably, TP53 was associated with the mismatch repair (MMR) gene in some cancers which contained truncating or nontruncating mutation. Based on the classification of truncating or nontruncating mutation, we also discovered that TP53 expression was positively or negatively correlated with the immune score, stromal score, and the levels of immune cell infiltration in different cancers. Conclusions. Our research reveals an overarching landscape of immunological value on TP53 status in various malignant tumors. According to our results, we demonstrate that TP53 also plays an immunological role in various cancers.


  • Tumor‐infiltrating lymphocytes‐based subtypes and genomic characteristics of EBV‐associated lymphoepithelioma‐like carcinoma

    by WenJuan Yin, JiaoYue Jin, Hua Bao, HanLin Chen, CanMing Wang, GuoPing Cheng, ChaoQi Wu, Meijuan Wu, Junrong Yan, Xue Wu, et al.

    Tumor‐infiltrating lymphocytes (TILs) offer a key for morphological diagnosis of lymphoepithelioma‐like carcinoma (LELC) and are the foundation of oncoimmunology. To date, no reports have found a specific risk stratification value of TILs and related it to genomic variation in LELC. Based on the stromal TILs (str‐TILs) ratio, we classified 105 Epstein–Barr virus (EBV)‐associated LELC cases into two subtypes: patients with ≥60% str‐TILs area ratio in tumor were classified as subtype I, and otherwise as subtype II. Subtype I patients had significantly better progression‐free survival (PFS) and overall survival (OS). We also explored the genomic characteristics of EBV‐associated LELC within different involved organs. We performed whole‐exome sequencing for 51 patients with enough tissue and analyzed the genomic characteristics of EBV‐associated LELC. Overall, EBV‐associated LELCs were characterized by a low somatic mutation rate and copy number variations; the enriched genetic lesions affected RTK‐RAS, PI3K, and cell cycle pathways. Moreover, EBV‐associated LELCs from different organs were more similar to each other genetically as compared with other traditional carcinomas of the same sites―as evidenced by unsupervised clustering based on the quantitative data from both mutation signature and chromosomal aneuploidies. Notably, EBV‐associated LELC patients with oncogenic driver alterations showed a worse prognosis compared with patients without such alterations. © 2022 The Pathological Society of Great Britain and Ireland.


  • [Pathological features related to onco-immunity and their clinical significance of pancreatic ductal adenocarcinoma].

    by C M Wang, C Y Xu, S Jiang, Q Zhou, Z J Jiang, G P Cheng, M J Wu, T T Feng, W J Yin

    Objective: To investigate the tumor immunity-related pathologic features and clinical significance in pancreatic ductal adenocarcinoma (PDAC). Methods: All pathologic materials and clinical information of 192 PDAC patients from the Cancer Hospital of the University of Chinese Academy of Sciences from January 2010 to December 2020 were collected. The onco-immune microenvironment associated morphologic features were evaluated, and MHC-Ⅰ, PD-L1, CD3, and CD8 expression were detected by immunohistochemistry (IHC). Then the correlation between the factors and their influence on prognosis was analyzed. Results: There were 163 cases of non-specific adenocarcinoma (163/192, 84.90%), 18 cases of adeno-squamous carcinoma (18/192, 9.37%), and 11 cases of other rare subtypes (11/192, 5.73%). Perineural invasion was observed in 110 cases (110/192, 57.29%) and vascular invasion in 86 cases (86/192, 44.79%). There were 84 cases (84/182, 46.15%) with severe chronic inflammation. Tumor infiltrating immune cell numbers (TII-N) were increased in 52 cases (52/192, 27.08%). Lymphocytes and plasma cells were the main infiltrating immune cells in 60 cases (60/192, 31.25%), whereas in 34 cases (34/192, 17.71%) the tumors were mainly infiltrated by granulocytes, and 98 cases (98/192, 51.04%) showed mixed infiltration. CD3+T cells were deficient in 124 cases (124/192, 66.31%). CD8+T cells were deficient in 152 cases (152/192, 79.58%). MHC-Ⅰ expression was down-regulated in 156 cases (156/192, 81.25%), and PD-L1 was positive (CPS≥1) in 46 cases (46/192, 23.96%). Statistical analysis showed that TII-N was negatively correlated with vascular invasion (P=0.035), perineural invasion (P=0.002), stage (P=0.004) and long-term alcohol consumption (P=0.039). The type of immune cells correlated positively with chronic pancreatic inflammation (P=0.002), and negatively with tumor differentiation (P=0.024). CD8+T cells were positively correlated with CD3+T cells (P=0.032), MHC-Ⅰ expression (PP=0.001), and negatively correlated with long-term smoking (P=0.016). Univariate analysis showed that histological nonspecific type (P=0.013) and TII-N (PP=0.032), perineural invasion (P=0.001), high stage (P=0.003) and long-term alcohol consumption (P=0.004) were adverse prognostic factors. COX multivariate risk analysis found that TII-N was an independent favorable factor for PDAC, while perineural invasion was an independent adverse risk factor. Conclusions: TII-N is an independent superior prognostic factor for PDAC, and significantly correlated with many factors; chronic alcohol consumption and smoking may inhibit onco-immunity in PDAC patients.